PATENT CLAIM ANALYSIS

Application Number: 15962752
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["424", "139100"]

Abstract:
The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Claim (Index 211):
A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of an antibody that specifically binds to human GITR, wherein the antibody comprises:\n (a) a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of X 1 YX 2 MX 3  (SEQ ID NO: 1), wherein X 1  is D, E, G or A; X 2  is A, V, L, I, P, F, M or Y; and X 3  is Y, G, N, Q, S, T, C, W, F or H; (b) a VH CDR2 comprising the amino acid sequence of X 1 IX 2 X 3 X 4 SGX 5 X 6 X 7 YX 8 QKFX 9 X 10  (SEQ ID NO: 2), wherein X 1  is V, A, L, I, P, F, M or T; X 2  is R, K, H, Q or A; X 3  is T, G, N, Q, S, C, W, Y, V, I or P; X 4  is Y, G, N, Q, S, T, C, W, F, H, or A; X 5  is D, E, G or A; X 6  is V, A, L, I, P, F, M or T; X 7  is T, G, N, Q, S, C, W, Y, V, I, P or A; X 8  is N, G, Q, S, T, C, W, Y or A; X 9  is K, R, H, Q or A; and X 10  is D, E, G or A; (c) a VH CDR3 comprising the amino acid sequence of SGTVRGX 1 X 2 X 3  (SEQ ID NO: 3), wherein X 1  is F, A, V, L, I, P, M, Y, W, H or S; X 2  is A, or D; and X 3  is Y, G, N, Q, S, T, C, W, F, H or V; (d) a light chain variable region (VL) CDR1 comprising the amino acid sequence of KSSQSX 1 X 2 X 3 X 4 X 5 X 6 X 7 KX 8 YLX 9  (SEQ ID NO: 4), wherein: X 1  is L, A, V, I, P, F or M; X 2  is L, A, V, I, P, F, M or 5; X 3  is N, G, Q, S, T, C, W, Y or A; X 4  is S, G, N, Q, T, C, W, Y or A; X 5  is G, N, Q, S, T, C, W, Y or A; X 6  is N, G, Q, S, T, C, W, Y or A; X 7  is Q, G, N, S, T, C, W, Y or A; X 8  is N, G, Q, S, T, C, W, Y or A; and X 9  is T, G, N, Q, S, C, W, Y, V, I or A; (e) a VL CDR2 comprising the amino acid sequence of X 1 ASTRX 2 X 3  (SEQ ID NO: 5), wherein: X 1  is W, G, N, Q, S, T, C, Y, F, H or A; X 2  is E, D or A; and X 3  is S, G, N, Q, T, C, W, Y or A; and (f) a VL CDR3 comprising the amino acid sequence of QX 1 X 2 YX 3 X 4 PYT (SEQ ID NO: 6), wherein: X 1  is N, G, Q, S, T, C, W or Y; X 2  is D, E or Y; and X 3  is S, G, N, Q, T, C, W, Y or A; and X 4  is Y, G, N, Q, S, T, C, W, F, H, L, or A.

Metadata:
- Claim Count in Document: 123.0
- Percentile: 91.0
- Lexical Diversity: 1.74545
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15962673', '14724452', '14472116', '11389880', '12753402']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7707665667872803
- 35 USC 102 Novelty (BERT): 0.6315304680269488
- Combined Prediction Score: 0.7568429569112471
- Mean Citation Score: 539.2658939999999
- Max Citation Score: 687.7104
- Similarity Product: 516.0836719882967

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test